Companion Animal Therapeutics Market Forecasts to 2034 - Global Analysis By Therapeutic Class, Animal Type, Indication, Route of Administration, Distribution Channel, Prescription Status, End User, and By Geography

According to Stratistics MRC, the Global Companion Animal Therapeutics Market is accounted for $12.3 billion in 2026 and is expected to reach $28.2 billion by 2034 growing at a CAGR of 10.9% during the forecast period. The market covers medicines used to treat acute, chronic and age-related conditions in companion animals, including parasiticides, anti-infectives, dermatology drugs, and pain therapies. It is used to manage disease, relieve symptoms and improve quality of life under veterinary supervision. Growth reflects rising pet healthcare expenditure. Supplier credibility, consistent quality, clear product information and dependable after-sales support will influence purchasing decisions.

Market Dynamics:

Driver:

Expansion of veterinary treatment options and earlier disease diagnosis

Expanding veterinary treatment options and earlier disease diagnosis are increasing demand for companion animal therapeutics. Better screening, owner awareness and diagnostic access allow chronic and age-related conditions to be identified sooner, creating demand for parasiticides, anti-infectives, dermatology drugs, pain therapies and endocrine treatments. Veterinary referral networks and specialty practice growth support more targeted prescribing. As pets live longer and owners accept higher care standards, demand is likely to remain broad across acute, chronic and preventive treatment categories.

Restraint:

High treatment costs and species-specific approval requirements

High treatment costs can discourage owners from starting or continuing therapy, particularly for chronic conditions and multi-pet households. Species-specific approval requirements, limited label indications and regulatory variation increase development and market-access costs for suppliers. Clinics may face formulary constraints, reimbursement uncertainty and owner price sensitivity. These factors can slow adoption of newer therapies and widen gaps between specialist and general practice. Cost-effective dosing, clear value communication and appropriately approved products are needed to support sustainable access across species.

Opportunity:

Targeted therapies and improved access to veterinary medicines

Targeted therapies and improved access can expand companion animal treatment across specialty and primary-care settings. Practitioner partnerships, online pharmacies and clinic-led follow-up can improve adherence and owner understanding. Condition-specific products and clearer labeling can differentiate offerings and support appropriate use. There is also scope to serve underserved life stages and multi-pet households through coordinated veterinary, retail and digital channels. Providers that combine evidence, safety and convenient access can strengthen referrals, retention and responsible use beyond major urban centers.

Threat:

Regulatory hurdles, antimicrobial stewardship and safety risks

Regulatory hurdles, antimicrobial stewardship and safety risks can constrain companion animal therapeutics. Stricter prescribing controls, resistance concerns and adverse-event scrutiny may limit some anti-infective and chronic-use products. Manufacturing standards, ingredient availability and online-platform policies can affect quality and distribution. Competition from lower-priced substitutes and inconsistent claims may undermine trust. Companies need robust pharmacovigilance, traceable sourcing, responsible promotion and clear evidence to protect reputation, support veterinarians and maintain market access across jurisdictions.

Covid-19 Impact:

The COVID-19 pandemic disrupted veterinary appointments, specialist retail, travel and pet-care supply chains, while shifting more purchasing and advice-seeking online. Some owners postponed non-urgent services, but increased time at home and heightened attention to animal wellbeing supported demand for home-use products and digital support. Providers responded with e-commerce, teleconsultation and flexible scheduling. As restrictions eased, in-person services recovered, but demand for convenience and clear product information remained. The effect varied by market, depending on clinical need, discretionary spending and reliance on in-person experiences where available.

The Parasiticides segment is expected to be the largest during the forecast period

The Parasiticides segment is expected to account for a leading share of the companion animal therapeutics market during the forecast period. Its position reflects the relevance of this group to the addressable companion-animal population and the breadth of use across the market's principal therapeutic class applications. Established product availability, owner familiarity and professional recommendations support demand, while a wide range of care needs encourages repeat purchasing or service use. Market participants are expected to prioritize this segment through targeted product development, broader distribution and clearer use guidance.

The Other Companion Animals segment is expected to have the highest CAGR during the forecast period

The Other Companion Animals segment is expected to have the highest CAGR during the forecast period as providers expand targeted solutions and improve access through veterinary, specialist retail and digital channels. Demand is supported by growing awareness of the relevant need, improved product formulation or service delivery, and increased owner willingness to invest in tailored companion-animal care. As evidence, convenience and availability improve, this segment may attract new entrants and encourage established providers to broaden their portfolios.

Region with largest share:

North America is expected to account for a leading share of the companion animal therapeutics market, supported by high companion-animal ownership, comparatively developed veterinary infrastructure, established pet specialty retail and relatively high per-pet expenditure. The United States represents a major demand center because owners have access to veterinary clinics, online pet-care platforms and a broad selection of specialized products and services. Canada contributes through a mature pet-care ecosystem and established companion-animal health providers. Market adoption is also supported by insurance availability, consumer awareness and product innovation, although adoption differs by income, geography and veterinary access.

Region with highest CAGR:

Asia Pacific is expected to exhibit strong growth in the companion animal therapeutics market as pet ownership, urban household formation, veterinary service availability and organized pet retail expand across major markets. China, Japan, South Korea, India and Australia offer different adoption pathways, reflecting differences in purchasing power, veterinary infrastructure, product regulation and the role of digital commerce. Growing awareness of preventive care and rising demand for premium companion-animal products are likely to support market development. Expansion will depend on localized products, professional education and compliance with national animal-health and consumer-protection requirements.

Key players in the market

Some of the key players in the Global Companion Animal Therapeutics Market include Zoetis Inc., Elanco Animal Health, Merck Animal Health, Boehringer Ingelheim Animal Health, Ceva Sante Animale, Virbac, Dechra Pharmaceuticals PLC, Vetoquinol, Norbrook Laboratories, Bimeda, Phibro Animal Health Corporation, Kyoritsu Seiyaku Corporation, Sichuan Yuanda Shuyang Pharmaceutical, Chanelle Pharma, KRKA d.d., IDEXX Laboratories, Inc., Covetrus, Inc., Ourofino Saude Animal.

Key Developments:

In July 2026, Royal Canin (Mars Petcare) launched its first fresh, fully cooked veterinary diet portfolio for dogs, addressing selected gastrointestinal needs, food sensitivities and reduced appetite through veterinarian-exclusive nutrition.

In May 2026, Elanco Animal Health began a phased U.S. launch of Befrena, an anti-IL-31 monoclonal antibody injection for dogs with allergic and atopic dermatitis.

In February 2026, Merck Animal Health announced FDA approval of NUMELVI, a second-generation JAK inhibitor for control of pruritus associated with allergic dermatitis in dogs.

Therapeutic Class Covered:

• Parasiticides
• Anti-Infectives
• Dermatology Therapeutics
• Pain and Anti-Inflammatory Drugs
• Cardiovascular and Endocrine Drugs

Animal Types Covered:

• Dogs
• Cats
• Equine Companion Animals
• Other Companion Animals

Indications Covered:

• Dermatology
• Orthopedic and Pain Conditions
• Oncology
• Cardiometabolic Disorders
• Infectious Diseases

Route of Administration Covered:

• Oral
• Injectable
• Topical
• Otic and Ophthalmic

Distribution Channels Covered:

• Veterinary Hospitals and Clinics
• Veterinary Distributors
• Retail and Online Veterinary Pharmacies
• Specialty Animal Health Platforms

Prescription Status Covered:

• Prescription-Only Therapeutics
• Over-the-Counter Veterinary Medicines
• Specialty and Biologic Therapies

End Users Covered:

• General Veterinary Clinics
• Specialty Veterinary Hospitals
• Veterinary Pharmacies and Distributors
• Animal Welfare and Shelter Programs

Regions Covered:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Netherlands
  • Belgium
  • Sweden
  • Switzerland
  • Poland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Malaysia
  • Singapore
  • Vietnam
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Colombia
  • Chile
  • Peru
  • Rest of South America
• Rest of the World (RoW)
  • Middle East
    • Saudi Arabia
    • United Arab Emirates
    • Qatar
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Egypt
    • Morocco
    • Rest of Africa

What our report offers:

• Market share assessments for regional and country-level segments
• Strategic recommendations for new entrants
• Covers market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032, and 2034
• Market trends, including drivers, constraints, opportunities, threats, challenges, investment opportunities, and recommendations
• Strategic recommendations for key business segments based on market estimations
• Competitive landscape mapping and assessment of key industry trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends and assessment of the latest technological advancements

Free Customization Offerings:

All customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, forecasts, and CAGR of any prominent country as per the client's interest (subject to feasibility assessment)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances